中国经济网北京1月8日讯 据同花顺数据显示，在刚过去的2025年12月份，博时恒生医疗保健 (QDII-ETF) 单月下跌10.17%。截至2025年三季度末规模为74.30亿元。 | 代码 名称 | | 12月复权单位 累计单位 | | | --- | --- | --- | --- | | | 净值增长率8 净值元 | | | | 513060. SH 博时恒生医疗保健(QDII-ETF) | -10.17 | 0.59 | 63.02 2021-03-18 万琼 | 来源：同花顺 2025年三季度前十大重仓股为百济神州、药明生物、信达生物、康方生物、中国生物制药、石药集 团、京东健康、三生制药、药明康德、阿里健康。基金经理万琼2004年起先后在中企动力科技股份有限 公司、华夏基金工作。2011年加入博时基金管理有限公司，历任投资助理、基金经理助理、基金经理。 （责任编辑：刘畅 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@s ...

Core Viewpoint - JD Health has formed a deep collaboration with domestic innovative drug company Kaiqi Xincheng Biopharmaceutical Technology Co., Ltd. to support the clinical cure of chronic hepatitis B patients in China [1] Group 1: Collaboration Details - The partnership will integrate JD Health's advantages in medical services and instant retail to provide comprehensive services for chronic hepatitis B patients [1] - Kaiqi Xincheng's innovative drug, the first globally to use HepDirectTM liver-targeting technology, is being launched exclusively on JD Health's platform [1] Group 2: Product Launch - The drug, named new Shumu® (甲磺酸普雷福韦片), is indicated for the treatment of adult chronic hepatitis B and has received support from national major new drug creation technology projects during the 12th and 13th Five-Year Plans [1] - The product aims to deliver active drugs directly to the liver, enhancing efficacy while reducing toxicity [1] Group 3: Clinical Research - Phase III clinical trial results indicate that the treatment group showed more effective and sustained viral suppression, with significant reductions in HBsAg levels [1]

中国经济网北京1月8日讯 据同花顺数据显示，在刚过去的2025年12月份，博时恒生医疗保健 (QDII-ETF) 单月下跌10.17%。截至2025年三季度末规模为74.30亿元。 来源：同花顺 (责任编辑：康博) 2025年三季度前十大重仓股为百济神州、药明生物、信达生物、康方生物、中国生物制药、石药集 团、京东健康、三生制药、药明康德、阿里健康。基金经理万琼2004年起先后在中企动力科技股份有限 公司、华夏基金工作。2011年加入博时基金管理有限公司，历任投资助理、基金经理助理、基金经理。 | 代码 名称 | 12月复权单位 累计单位 规模亿元 基金成立日 基金经理 | | --- | --- | | | 净值增长率8 净值元 | | 513060.SH 博时恒生医疗保健(QDII-ETF) | -10.17 0.59 63.02 2021-03-18 万琼 | ...

Core Insights - JD Health has formed a deep collaboration with local innovative pharmaceutical company Kaiqi Xincheng Biopharmaceutical Technology Co., Ltd. to support the clinical cure of chronic hepatitis B patients in China [1][2] - The collaboration will leverage JD Health's strengths in medical services and instant retail, launching two innovative drugs: the first-class drug Adefovir Dipivoxil Tablets (brand name: Xinshumu®) and a zinc-selenium multivitamin soft capsule (brand name: Kaimumu®) [1][2] Drug Launch Details - Adefovir Dipivoxil Tablets (Xinshumu®) are designed for the treatment of adult chronic hepatitis B and have received support from national major new drug creation technology projects during the "12th Five-Year" and "13th Five-Year" plans [1] - Clinical trial results indicate that the drug effectively and persistently inhibits the virus, with a significantly higher proportion of patients achieving HBsAg levels below 1000 IU/mL compared to the control group (P<0.05) and other similar drugs [1] - The zinc-selenium multivitamin soft capsule (Kaimumu®) is formulated for liver nutrition and is rich in nine vitamins and two minerals, designed for easy absorption and convenient daily use [2] Service Integration - JD Health will utilize its ecosystem of "online consultation + pharmaceutical retail + instant delivery" to create a service loop that includes professional supply, online specialist guidance, and rapid delivery, facilitating the widespread availability of the new drugs [2] - Patients can purchase these new drugs through the JD APP or JD pharmacies nationwide with a valid prescription starting immediately [2] Strategic Goals - JD Health aims to enhance the overall efficiency and quality of the pharmaceutical supply chain through ongoing strategic collaboration with Kaiqi Xincheng, optimizing the patient experience [2] - The company is committed to providing high-quality pharmaceutical health products and services, contributing to the "Healthy China 2030" strategic goals by improving the accessibility of innovative drugs [3]

Core Viewpoint - JD Health has formed a deep collaboration with local innovative pharmaceutical company Kaiji Xincheng Biopharmaceutical Technology Co., Ltd. to support the clinical cure of chronic hepatitis B patients in China through integrated resources in medical services and instant retail [1][2]. Group 1: Product Launch and Features - JD Health and Kaiji Xincheng have launched the first-class innovative drug, Mesylate Prefofovir Tablets (brand name: Xinshumu), which targets chronic hepatitis B treatment using HepDirectTM liver-targeting technology [1]. - The drug has received significant support from national major new drug creation technology projects during the "12th Five-Year" and "13th Five-Year" plans, demonstrating its efficacy in delivering active ingredients directly to the liver, enhancing effectiveness while reducing toxicity [1]. - Phase III clinical trial results indicate that the drug shows stronger and more durable viral suppression compared to the control group, with a significantly higher proportion of patients achieving HBsAg levels below 1000 IU/mL (P<0.05) [1]. Group 2: Nutritional Supplement - The Zinc-Selenium Multivitamin Soft Gel Capsules (brand name: Kaimumu) are designed for liver nutrition and suitable for individuals needing supplementation of zinc, selenium, and various vitamins [2]. - This product contains nine vitamins and two minerals, scientifically proportioned and packaged in soybean lecithin capsules for better absorption, with a recommended dosage of two capsules daily [2]. Group 3: Service Integration and Strategy - JD Health will leverage its ecosystem of "online consultation + pharmaceutical retail + instant delivery" to provide a comprehensive service loop, ensuring rapid dissemination of the new drugs to patients [2]. - The collaboration aims to optimize the overall patient service experience and enhance the efficiency and quality of the pharmaceutical supply chain, promoting a win-win development [2]. - JD Health is committed to providing high-quality pharmaceutical health products and services, enhancing the accessibility of innovative drugs to a broader patient population [2][3]. Group 4: Future Outlook - JD Health's value effect as the "first station for new special drug launches" continues to expand, facilitating access to cutting-edge innovative drugs through integrated online and offline channels [3]. - The company plans to collaborate with global pharmaceutical partners to improve the accessibility of new special drugs, contributing to the "Healthy China 2030" strategic goals [3].

Core Viewpoint - JD Health has entered into a deep collaboration with local innovative pharmaceutical company Kaiji Xincheng Biopharmaceutical Technology Co., Ltd. to enhance the treatment options for chronic hepatitis B patients in China [1][2]. Group 1: Partnership and Product Launch - The collaboration aims to integrate JD Health's strengths in medical services and instant retail to support clinical cure goals for chronic hepatitis B patients [1]. - The first launch of the innovative drug, Mesylate Prefofovir Tablets (brand name: Xinshumu®), and Zinc-Selenium Multivitamin Soft Capsules (brand name: Kaimumu®) will be exclusive to JD Health's platform [1][2]. - Mesylate Prefofovir Tablets are designed for adult chronic hepatitis B treatment and have received significant support from national major new drug creation technology projects [1]. Group 2: Clinical Efficacy and Product Features - Phase III clinical trial results indicate that the drug effectively suppresses the virus more powerfully and durably, with a significantly higher proportion of patients achieving HBsAg levels below 1000 IU/mL compared to the control group (P<0.05) [1]. - The Zinc-Selenium Multivitamin Soft Capsules are formulated to support liver health and are rich in various vitamins and minerals, designed for easy absorption [2]. Group 3: Service Integration and Future Plans - JD Health will leverage its ecosystem of "online consultation + pharmaceutical retail + instant delivery" to create a comprehensive service loop for the new drugs, ensuring rapid accessibility for patients [2]. - The company plans to continue deepening strategic collaboration with Kaiji Xincheng to optimize patient service experiences and enhance the overall efficiency and quality of the pharmaceutical supply chain [2][3]. - JD Health aims to contribute to the "Healthy China 2030" strategic goals by improving the accessibility of innovative drugs through partnerships with global pharmaceutical companies [3].

摘要 京东健康已成为中国最大的线上 B2C 零售药店，并积极发展 O2O 和线 下药房业务，构建了"医+药"双轮驱动的互联网医疗生态系统，未来 发展空间广阔。 京东健康背靠京东集团，在供应链和用户导流方面具备显著优势，同时 已成为创新药和新特药的首发平台，吸引了大量优质产品，提升了在患 者和药企中的认可度。 京东健康通过自营 B2C、在线平台及 O2O 业务实现全渠道布局，2025 年上半年即使线下市场不景气，仍实现了超过 20%的收入和利润增长， Non-GAAP 净利润率超过 8%。 中国处方外流和线上化趋势明显，网上药店市场销售额持续增长，B2C 互联网药店市占率显著提升，京东健康自营 B2C 业务通过快速配送和创 新产品巩固品牌优势，活跃用户数量稳步增长至 1.8 亿人次。 京东健康在线平台通过增加第三方商家数量丰富产品供给，O2O 业务覆 盖全国 20 万家药店，覆盖接近 2 亿人群，满足即时买药需求，增强市 场竞争力。 Q&A 京东健康在互联网医疗领域的地位和发展前景如何？ 京东健康是互联网医疗领域的绝对龙头企业，特别是在 AI 时代具备良好的发展 前景。自 IPO 以来，其收入从 300 亿人民 ...

三只新股首日上市均高开，天数智芯高开31.54%，精锋医疗-B高开36.45%，智谱高开3.27%。 | < W | 天数智芯(9903) | | | | | --- | --- | --- | --- | --- | | | 集合竞价 01-08 09:20:08 | | | | | 190.200 | 额 4.14亿 股本 2.54亿 市盈 -40.2 | | 万得 | | | +45.600 +31.54% | 换 0.90% 市值1483亿 市净 17.53 | | 型口 | | | 分时 五日 | 日K | 周K 月K | 电子 | | | 置加 | | 均价:187.905 盘口 | 成交 | | | 200.000 | | 38.31% - | | 0.00(0) | | | | 卖9 191.800 | | 0.00(0) | | | | 卖8 191.700 | | 0.00(0) | | | | 卖7 191.600 | | 0.00(0) | | | | 卖6 191.500 | | 0.00(0) | | | | 卖5 191.400 | | 0.00(0) | | 144.600 | ...

Group 1 - The Hong Kong stock market experienced a short-term pullback, with leading tech stocks declining, while the Hong Kong Internet ETF (513770) saw a price drop of 2.54% but recorded a net inflow of 272 million yuan during the dip, reaching a historical high of 13.305 billion yuan in fund size [1][3] - The Hong Kong Internet ETF (513770) passively tracks the CSI Hong Kong Internet Index, with major holdings including Alibaba-W, Tencent Holdings, and Xiaomi Group-W, where the top ten weighted stocks account for over 78% of the total [3][4] - Notably, southbound funds showed a contrary net inflow of 9.178 billion yuan, with Tencent Holdings and Xiaomi Group-W receiving significant increases in positions of 1.955 billion and 1.633 billion HKD, respectively [4] Group 2 - The AI video featuring dancing pets has gained significant traction in overseas markets, leading to a 102% increase in daily revenue for Kuaishou's AI mobile platform compared to December 2025. JPMorgan highlighted Kuaishou's leading position in generative AI, labeling it as "one of the cheapest AI stocks globally" [5] - Citigroup's report favored Tencent Holdings and Alibaba-W as core AI concept stocks, optimistic about Tencent's AI development prospects in enterprise and user applications, and Alibaba's growth in cloud revenue and efficiency [5] - Industrial Securities indicated that internet leaders are poised to be the frontrunners in China's AI sector, expecting a resonance of buying from both domestic and foreign investors, which could lead to an upward adjustment in long-term profit growth expectations and valuation improvements [5]

Group 1: Core Insights - Traditional industries are the backbone of China's manufacturing sector, accounting for approximately 80% of key indicators such as value added and employment [1] - The transformation of traditional industries towards high-end, intelligent, and green development is essential for building a modern industrial system [1] Group 2: Cost Reduction and Efficiency Improvement - In Zhengzhou, the use of intelligent manufacturing systems has led to a 10% to 15% increase in production efficiency and a 5% to 10% reduction in delivery cycles, with overall costs decreasing by 3% to 5% [2] - Traditional industries are shifting from relying on scale and experience to a data-driven approach that integrates hardware and software ecosystems [2] Group 3: Smart Factory Development - Over 35,000 basic-level and more than 7,000 advanced-level smart factories have been established since the start of the 14th Five-Year Plan, significantly enhancing production efficiency and reducing costs [3] - Continuous investment in new technology and the application of AI and smart technologies are crucial for traditional industries to enhance their high-end and intelligent capabilities [3] Group 4: Green Development Opportunities - The "dual carbon" goals are driving traditional industries to transition from resource dependency to technology value addition, creating new growth opportunities through smart and green technologies [4] - By 2024, the utilization of recycled resources such as waste steel and waste copper is expected to exceed 400 million tons, highlighting the push for industrial decarbonization and green growth [4] Group 5: Energy Transition and Circular Economy - Traditional energy companies are encouraged to explore clean energy development, while steel companies can utilize recycled materials to reduce costs and emissions [5] - The development of carbon trading markets presents opportunities for traditional industries to profit from energy-saving and emission-reduction efforts [5] Group 6: Consumer Market Dynamics - The expanding consumer market is providing new opportunities for traditional industries, emphasizing the need for precise alignment of production with consumer preferences [7] - The demand for higher quality and diverse products is driving traditional industries to innovate and enhance product offerings [8] Group 7: Value Enhancement Challenges - The ultimate goal for traditional industries is to address the challenge of value enhancement through technological innovation and brand building [9] - Improving product quality and brand premium capabilities are essential for driving value enhancement in traditional enterprises [9]